Abstract 627P
Background
The prevalence of multiple primary neoplasms has been increasing over time, with primary colorectal cancer and primary prostate cancer being a common coexistence. Notably, a primary prostatic cancer was discovered in approximately one-sixth of men who underwent prostate cancer screening prior to rectal cancer excision. Due to a lack of knowledge about the racial disparity factor in this multiple primary malignancy, our study aims to assess the risk of developing primary prostate cancer between African Americans and Caucasians in patients with colorectal cancer.
Methods
We extracted the data from cancer registries in the Surveillance, Epidemiology, and End Results (SEER) database for patients with primary colorectal cancer from 2000-2020. This allowed us to compare the risk of developing primary prostate cancer between African American and Caucasian individuals. We used MP-SIR session to estimate the SIR (standardized incidence ratios) as observed/expected (O/E), and excess absolute risk (EAR) per 10,000 patients using 95% Confidence intervals (CI), with significant result when p <0.05. The latency exclusion period was set at 0 month.
Results
Among 721,385 patients included in the study with primary colorectal cancer, only 8,943 (1.24%) developed primary prostate cancer (Expected= 8,938.87, O/E= 1.00, p >0.05, 95% CI: 0.98-1.02, EAR= 0.01). Out of these cases, approximately 7,340 (82.1%) were Caucasian individuals who developed primary prostate cancer (Expected= 7,633.79, O/E= 0.96, p <0.05, 95% CI: 0.94-0.98, EAR= -1.03), while only 1,603 (17.9%) were African American individuals who developed primary prostate cancer (Expected= 1,305.08, O/E= 1.23, P <0.05, 95% CI: 1.17-1.29, EAR= 7.82). Notably, at the age of 70-74 years, Caucasian individuals exhibited a significant decrease in the risk of developing primary prostate cancer (O/E= 0.91, P <0.05, EAR= -4.12), whereas African American individuals showed a significant increase in risk at this age (O/E= 1.27, P <0.05, EAR= 14.32).
Conclusions
Our results show a higher risk of developing primary prostate cancer in African American patients compared to Caucasian patients. Further research is needed to better understand the race variations on a genetic basis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
122P - Distinct transcriptomic immune profiling and clinicopathological features of cribriform morphology in colorectal adenocarcinomas
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract
123P - Spatial molecular profiling identifies FGF20 upregulation on cancer-associated fibroblast and FGFR2-PI3K/Akt activation in tumor cells of sporadic early-onset colon cancer
Presenter: Dave Hoon
Session: Poster Display
Resources:
Abstract
124P - Characteristics, prognosis and therapeutic effects of non-V600 BRAF mutated colorectal cancer
Presenter: Lalida Arsa
Session: Poster Display
Resources:
Abstract
125P - Final results of APOLLON-11 and SOYUZ-APOLLON study: Multicentre prospective observational post-authorization study of bevacizumab biosimilar in patients with metastatic colorectal cancer in real-world practice
Presenter: Alexey Tryakin
Session: Poster Display
Resources:
Abstract
126P - From tumor height (TH) to tumor regression grade (TRG) in locally advanced rectal cancers (LARC) during total neadjuvant therapy (TNT): A retrospective analysis
Presenter: Valeria Pusceddu
Session: Poster Display
Resources:
Abstract
127P - A meta-analysis of efficacy and safety from head-to-head first-line (1L) trials of epidermal growth factor receptor inhibitors (EGFRIs) versus bevacizumab in combination with chemotherapy (CT) doublets in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) by sidedness
Presenter: Takayuki Yoshino
Session: Poster Display
Resources:
Abstract
128TiP - A phase II study of cadonilimab + FOLFOXIRI and bevacizumab as initial therapy for unresectable proficient mismatch repair/microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC)
Presenter: Rongbo Lin
Session: Poster Display
Resources:
Abstract
140P - Prevalence of claudin-18 isoform 2 (CLDN18.2) positivity in locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mg/GEJ) adenocarcinoma in patients (pts) in the Asia region: Phase III SPOTLIGHT and GLOW studies
Presenter: Hoo Hwoei Fen Soo
Session: Poster Display
Resources:
Abstract
141P - Early phase trials outcomes in refractory upper GI cancers: A 10-year analysis from the SCRI UK phase I unit
Presenter: Antonella Cammarota
Session: Poster Display
Resources:
Abstract
142P - The survival impact of the addition of durvalumab to cisplatin/gemcitabine in advanced biliary tract cancer: A real-world, retrospective, multicentric study
Presenter: Silvia Foti
Session: Poster Display
Resources:
Abstract